Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Kaplan-Meier method

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44343   clinical trials with a EudraCT protocol, of which   7372   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    187 result(s) found for: Kaplan-Meier method. Displaying page 2 of 10.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2018-002374-46 Sponsor Protocol Number: UC-0110/1807 Start Date*: 2018-11-09
    Sponsor Name:UNICANCER
    Full Title: A randomised phase II trial assessing REGorafenib combined with IRInotecan as second-line treatment in patients with metastatic gastro-oesophageal adenocarcinomas.
    Medical condition: Patients aged ≥18 years old with metastatic gastro-oesophageal adenocarcinomas after failure of a first-line fluoropyrimidine and platinum-based chemotherapies.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-002852-34 Sponsor Protocol Number: S61508 Start Date*: 2020-02-10
    Sponsor Name:UZLeuven
    Full Title: Progression-free Survival after Minimally Invasive Surgical Microwave Ablation plus Durvalumab (MEDI4736) and Tremelimumab for Unresectable Non-metastatic Locally Advanced Pancreatic Cancer. MIMIPA...
    Medical condition: Unresectable Locally Advanced Non Metastatic Pancreatic Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10033606 Pancreatic cancer non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2007-000281-21 Sponsor Protocol Number: H6Q-MC-S039 Start Date*: 2007-09-05
    Sponsor Name:Eli Lilly and Company
    Full Title: Enzastaurin (LY317615) Before and Concomitant with Radiation Therapy, Followed by Enzastaurin Maintenance Therapy in Patients with Newly Diagnosed Glioblastoma without Methylation of the Promoter G...
    Medical condition: primary glioma without methylation of the promoter gene of MGMT enzyme
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018336 Glioblastoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2022-003063-21 Sponsor Protocol Number: ENX-CL-04-002a Start Date*: 2023-02-14
    Sponsor Name:Enlivex Therapeutics RDO, Ltd.
    Full Title: A Phase 1/2a Study Evaluating Allocetra-OTS as Monotherapy or in Combination with Anti-PD-1 Therapy for the Treatment of Advanced Solid Tumor Malignancy
    Medical condition: Advanced Solid Tumor Malignancy
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10065147 Malignant solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-002893-23 Sponsor Protocol Number: H8Z-MC-JACS Start Date*: 2009-09-03
    Sponsor Name:Eli Lilly and Company
    Full Title: An Open Label Single Arm Phase 1b/2 Study with Pharmacokinetic Sampling to Evaluate LY2181308 in Patients with Advanced Hepatocellular Carcinoma
    Medical condition: Hepatocellular Carcinoma (HCC)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-003773-42 Sponsor Protocol Number: PM1183-B-005-14 Start Date*: 2015-03-30
    Sponsor Name:Pharma Mar S.A. Sociedad Unipersonal
    Full Title: A Multicenter Phase II Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors.
    Medical condition: Selected Advanced Solid Tumors.
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10048683 Advanced cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) BE (Completed) SE (Completed) GB (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2019-003509-80 Sponsor Protocol Number: IMGN853-0416 Start Date*: 2020-09-07
    Sponsor Name:ImmunoGen, Inc.
    Full Title: MIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Periton...
    Medical condition: Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061269 Malignant peritoneal neoplasm PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061328 Ovarian epithelial cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10016180 Fallopian tube cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed) BG (Completed) GB (GB - no longer in EU/EEA) FR (Trial now transitioned) DE (Completed) PL (Completed) PT (Completed) NL (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-012280-34 Sponsor Protocol Number: 26866138-LYM-2034 Start Date*: 2009-12-04
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A Randomized, Open-Label, Multicenter, Phase 2 Study of the Combination of VELCADE, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (VR-CAP) or Rituximab, Cyclophosphamide, Doxorubicin, ...
    Medical condition: Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012818 Diffuse large B-cell lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) PT (Completed) CZ (Completed) DE (Completed) FR (Completed) ES (Completed) IT (Completed) IE (Completed)
    Trial results: View results
    EudraCT Number: 2017-002887-42 Sponsor Protocol Number: EORTC-1612-MG Start Date*: 2018-06-28
    Sponsor Name:European Organisation for Research and Treatment of Cancer
    Full Title: Combination of targeted therapy (encorafenib and binimetinib) followed by combination of immunotherapy (ipilimumab and nivolumab) vs immediate combination of immunotherapy in patients with unresect...
    Medical condition: BRAF V600 mutation–positive unresectable or metastatic melanoma.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025650 Malignant melanoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (GB - no longer in EU/EEA) DE (Trial now transitioned) PL (Trial now transitioned) NL (Trial now transitioned) DK (Completed) ES (Ongoing) IT (Trial now transitioned) FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-000266-11 Sponsor Protocol Number: 2012-772 Start Date*: 2014-05-27
    Sponsor Name:HOSPICES CIVILS DE LYON
    Full Title: Multicenter, randomized trial of carboplatin +/- paclitaxel in vulnerable elderly patients with stage III-IV advanced ovarian cancer.
    Medical condition: Vulnerable elderly women with newly diagnosed stage III-IV ovarian cancer after an initial debulking surgery or with a planned interval debulking surgery.
    Disease:
    Population Age: Elderly Gender: Female
    Trial protocol: IT (Completed) IE (Completed) DK (Prematurely Ended) FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-003109-73 Sponsor Protocol Number: TL-895-203 Start Date*: 2021-02-15
    Sponsor Name:Telios Pharma, Inc.
    Full Title: An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of TL-895 Combined with KRT-232 in Subjects with Relapsed/Refractory (R/R) FLT3+ Acute Myeloid Leukemia (AML)
    Medical condition: Relapsed/Refractory (R/R) FLT3+ Acute Myeloid Leukemia
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10081514 Acute myeloid leukemia refractory LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Prematurely Ended) AT (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-001499-20 Sponsor Protocol Number: RV-MM-GMSG-392 Start Date*: 2014-09-30
    Sponsor Name:Meletios-Athanasios Dimopoulos
    Full Title: A phase II open label, non comparative, non randomized study for the assessment of the efficacy and safety of lenalidomide + adriamycine and low dose dexamethasone combination (RAD) in newly diagno...
    Medical condition: Newly Diagnosed multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed)
    Trial results: View results
    EudraCT Number: 2005-002541-39 Sponsor Protocol Number: 3005011 Start Date*: 2005-08-24
    Sponsor Name:Orion Corporation
    Full Title: A Prospective, Multi-Centre, Randomised, Double-Blind Comparison of intravenous Dexmedetomidine with Propofol/Midazolam for continous sedation (24 hours to 14 days) of ventilated Patients in Intens...
    Medical condition: Patients requiring mechanical ventilation and sedation in ICU.
    Disease: Version SOC Term Classification Code Term Level
    8.0 10039897 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-000809-23 Sponsor Protocol Number: AB12003 Start Date*: 2014-10-10
    Sponsor Name:AB Science
    Full Title: A prospective, multicenter, randomized, double blind, placebo-controlled, 2-parallel groups, phase 3 study to compare the efficacy and safety of masitinib in combination with docetaxel to placebo i...
    Medical condition: metastatic Castrate Resistant Prostate Cancer (mCRPC).
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: ES (Restarted) SK (Prohibited by CA) GR (Completed) CZ (Completed) GB (Temporarily Halted) IT (Suspended by CA)
    Trial results: (No results available)
    EudraCT Number: 2019-001862-13 Sponsor Protocol Number: AB19001 Start Date*: 2020-03-12
    Sponsor Name:ABScience
    Full Title: A prospective, multicenter, randomised, double-blind, placebo-controlled, parallel groups, phase 3 study to compare the efficacy and safety of masitinib in combination with Riluzole versus placebo ...
    Medical condition: patients suffering from Amyotrophic Lateral Sclerosis (ALS)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10002026 Amyotrophic lateral sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SI (Completed) FR (Trial now transitioned) BE (Prematurely Ended) SE (Trial now transitioned) GB (GB - no longer in EU/EEA) PT (Ongoing) ES (Restarted) DK (Trial now transitioned) PL (Ongoing) IE (Prematurely Ended) IT (Prematurely Ended) NO (Trial now transitioned) GR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2005-003265-16 Sponsor Protocol Number: CA184-022 Start Date*: 2006-07-04
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Randomized, Double-Blind, Multi-center, Phase II Fixed Dose Study of Multiple Doses of Ipilimumab (MDX-010) Monotherapy in Patients with Previously Treated Unresectable Stage III or IV Melanoma ...
    Medical condition: Previously treated unresectable Stage III or IV Melanoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (Completed) DE (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2011-001017-13 Sponsor Protocol Number: CNIO-GI-01-2011 Start Date*: 2011-08-08
    Sponsor Name:CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS
    Full Title: Phase II trial of individualized selection of chemotherapy in patients with advanced pancreatic carcinoma based on the identification of therapeutic targets in tumor tissue
    Medical condition: Advanced pancreatic cancer
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059326 Pancreatic carcinoma stage IV PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2005-005475-14 Sponsor Protocol Number: 1144 Start Date*: 2005-10-17
    Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
    Full Title: INTEnsification Radiotherapy with Accelerated fractionation or ChemoTherapy And Local Excision After 3D External Radio-chemotherapy
    Medical condition: rectal cancer
    Disease: Version SOC Term Classification Code Term Level
    6.1 10038038 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-017871-13 Sponsor Protocol Number: ME GD 203 Start Date*: 2010-10-05
    Sponsor Name:New Medical Enzymes AG
    Full Title: A multicenter phase II study to evaluate safety and efficacy of glutadon once weekly (GDO) in patients with metastatic colorectal cancer resistant or intolerable to approved chemo- and molecular-ta...
    Medical condition: Adult patients with unresectable or metastatic colorectal cancer showing progression of disease on at least one fluoropyrimidine derivative, oxaliplatin, irinotecan and EGFR-antibodies (cetuximab o...
    Disease: Version SOC Term Classification Code Term Level
    12.1 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2012-004539-22 Sponsor Protocol Number: 11-2012 Start Date*: 2013-03-18
    Sponsor Name:I.T.M.O. - ITALIAN TRIALS IN MEDICAL ONCOLOGY
    Full Title: An open label, single arm, phase II study to evaluate the activity and toxicity of Panitumumab in pre-treated patients with advanced well differentiated neuroendocrine tumor (G1 and G2)
    Medical condition: Well differentiated neuroendocrine tumor (G1 and G2)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052399 Neuroendocrine tumour PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon Jun 16 05:31:49 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA